Nasal vaccine devices have the potential to offer more convenient and more effective protection against a variety of viruses.

Today the Coalition for Epidemic Preparedness Innovations (CEPI) announced an award of $5 million funding award to Ethris, a ...

The FDA has accepted for review the NDA for bumetanide nasal spray for edema associated with CHF, as well as hepatic and renal disease.

The trial will evaluate the safety and effectiveness of a next-generation vaccine administered through a nasal spray or ...

Despite the recently reported national decline in opioid overdose deaths, many U.S. communities, including New Orleans, continue to see an ...

If approved, the nasal spray formulation would provide an additional ... A Prescription Drug User Fee Act target date of September 14, 2025 has been assigned to the application.

PHOENIX (AZFamily) — A ketamine-derived nasal spray is now available for the millions of Americans living with severe depression. The hallucinogenic drug is an option when traditional treatment ...

Dose-dependent target engagement: ETH47 exhibited a clear dose-dependent ... and uniquely designed to be administered locally to the respiratory tract through inhalation or nasal spray using Ethris’ ...

for its novel Bumetanide Nasal Spray (RSQ-777). The FDA has assigned a Prescription Drug User Fee Act (PDUFA) target action date of September 14, 2025. This NDA acceptance represents a pivotal ...

9NEWS Medical Expert Dr. Payal Kohli weighs in on a new nasal spray being used to treat depression. 14 Outdated Home Trends That Are Lowering Your Property Value ...

Johnson & Johnson's nasal spray received US FDA approval The nasal spray is used for the treatment of major depressive disorder The drug brought in sales of $780 million in 2024 The US Food and Drug ...